EU Patent Rules May Tighten Following AstraZeneca Losec Abuse Case
This article was originally published in The Pink Sheet Daily
The Opinion of the Advocate General of the Court of Justice of the European Union that AstraZeneca tried to hold generic omeprazole off the market could make patent acquisitions more difficult and could impede pharmaceutical innovation.
You may also be interested in...
The European Court of Justice sides with the European Commission: manipulating the patent and regulatory systems to block competitors gets AZ a slap on the wrist and serves as a warning to others.
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.